Insightec’s Exablate Neuro is claimed to be first MR-guided focused ultrasound device approved by the FDA
Israel-based medical device company Insightec has closed a $150m Series F financing round, led by Koch Disruptive Technologies (KDT) for its Exablate Neuro incisionless neurosurgery device.
Koch Disruptive Technologies (KDT), a subsidiary of Koch, Inc., led the funding round with a $100m investment, bringing Insightec’s post-money valuation to $1.3bn.
The funding marks KDT’s second direct investment in INSIGHTEC.